TY - JOUR
T1 - “What else can we do?”—Provider perspectives on treatment-resistant depression in late life
AU - Hamm, Megan E.
AU - Karp, Jordan F.
AU - Lenard, Emily
AU - Dawdani, Alicia
AU - Lavretsky, Helen
AU - Lenze, Eric J.
AU - Mulsant, Benoit H.
AU - Reynolds, Charles F.
AU - Roose, Steven P.
AU - Brown, Patrick J.
N1 - Funding Information:
Research reported in this publication was funded through a Patient‐Centered Outcomes Research Institute (PCORI) Award (TRD‐1511‐33321). Funding information
Funding Information:
Dr. Karp has served as a scientific advisor in 2020 for NightWare, prepared and delivered a webinar (disease‐state, not product‐focused) for Otsuka in 2020, serves as scientific advisor for Aifred Health with potential for future equity, and receives compensation for editorial duties from Physician's Postgraduate Press and from American Journal of Geriatric Psychiatry. Dr. Lavretsky receives grant support from the NIH (NCCIH and NIMH), Forest Research Institute and the Alzheimer's Research and Prevention Foundation. Dr. Lenze has received research support from NIH, FDA, McKnight Brain Research Foundation, Taylor Family Institute for Innovative Psychiatric Research, Barnes Jewish Foundation, Takeda, and Lundbeck. Dr. Mulsant holds and receives support from the Labatt Family Chair in Biology of Depression in Late‐Life Adults at the University of Toronto. He currently receives research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient‐Centered Outcomes Research Institute (PCORI), the U.S. National Institute of Health (NIH), Capital Solution Design LLC (software used in a study founded by CAMH Foundation), and HAPPYneuron (software used in a study founded by Brain Canada). Within the past 5 years, he has also received research support from Eli Lilly (medications for a NIH‐funded clinical trial) and Pfizer (medications for a NIH‐funded clinical trial). He has been an unpaid consultant to Myriad Neuroscience. The other authors report no conflicts of interest.
Funding Information:
Dr. Karp has served as a scientific advisor in 2020 for NightWare, prepared and delivered a webinar (disease-state, not product-focused) for Otsuka in 2020, serves as scientific advisor for Aifred Health with potential for future equity, and receives compensation for editorial duties from Physician's Postgraduate Press and from American Journal of Geriatric Psychiatry. Dr. Lavretsky receives grant support from the NIH (NCCIH and NIMH), Forest Research Institute and the Alzheimer's Research and Prevention Foundation. Dr. Lenze has received research support from NIH, FDA, McKnight Brain Research Foundation, Taylor Family Institute for Innovative Psychiatric Research, Barnes Jewish Foundation, Takeda, and Lundbeck. Dr. Mulsant holds and receives support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He currently receives research support from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute (PCORI), the U.S. National Institute of Health (NIH), Capital Solution Design LLC (software used in a study founded by CAMH Foundation), and HAPPYneuron (software used in a study founded by Brain Canada). Within the past 5 years, he has also received research support from Eli Lilly (medications for a NIH-funded clinical trial) and Pfizer (medications for a NIH-funded clinical trial). He has been an unpaid consultant to Myriad Neuroscience. The other authors report no conflicts of interest.
Publisher Copyright:
© 2021 The American Geriatrics Society.
PY - 2022/4
Y1 - 2022/4
N2 - Background: Treatment-resistant depression in late-life (TRLLD) is common. Perspectives of primary care providers (PCPs) and psychiatrists treating TRLLD could give insights into the challenges and potential solutions for managing this condition. Methods: To identify perspectives of providers who treat TRLLD, we conducted a qualitative descriptive study using semi-structured interviews with providers treating older adults with TRLLD in five locations across North America (i.e., Los Angeles, New York City, Pittsburgh, St. Louis, and Toronto). We conducted semi-structured interviews with 50 care providers (24 primary care providers [PCPs], 22 psychiatrists, and 4 depression care managers). Interviews elicited providers' perspectives on treatment options for TRLLD, including treatment within the primary care setting and referral to psychiatry, and sought suggestions for improvement. Results: We identified four themes. (1) Treating TRLLD takes an emotional toll on providers; (2) existing psychiatric services are inadequate to meet the needs of patients with TRLLD, mainly because of lack of access; (3) PCPs often attempt to treat TRLLD, even when they are not comfortable doing so; and (4) to better meet the needs of patients with TRLLD, providers recommend integrated care models involving PCPs, psychiatrists, and psychotherapists, potentially made more feasible by the growth of telehealth. Conclusions: Findings from these qualitative interviews show the challenges in providing care for TRLLD. These findings can guide knowledge dissemination to psychiatrists, PCPs, policy-makers, and other stakeholders involved in the mental health system. They can also inform structural changes to clinical practice that may increase the implementation of the best treatment strategies across settings to improve long-term outcomes for TRLLD.
AB - Background: Treatment-resistant depression in late-life (TRLLD) is common. Perspectives of primary care providers (PCPs) and psychiatrists treating TRLLD could give insights into the challenges and potential solutions for managing this condition. Methods: To identify perspectives of providers who treat TRLLD, we conducted a qualitative descriptive study using semi-structured interviews with providers treating older adults with TRLLD in five locations across North America (i.e., Los Angeles, New York City, Pittsburgh, St. Louis, and Toronto). We conducted semi-structured interviews with 50 care providers (24 primary care providers [PCPs], 22 psychiatrists, and 4 depression care managers). Interviews elicited providers' perspectives on treatment options for TRLLD, including treatment within the primary care setting and referral to psychiatry, and sought suggestions for improvement. Results: We identified four themes. (1) Treating TRLLD takes an emotional toll on providers; (2) existing psychiatric services are inadequate to meet the needs of patients with TRLLD, mainly because of lack of access; (3) PCPs often attempt to treat TRLLD, even when they are not comfortable doing so; and (4) to better meet the needs of patients with TRLLD, providers recommend integrated care models involving PCPs, psychiatrists, and psychotherapists, potentially made more feasible by the growth of telehealth. Conclusions: Findings from these qualitative interviews show the challenges in providing care for TRLLD. These findings can guide knowledge dissemination to psychiatrists, PCPs, policy-makers, and other stakeholders involved in the mental health system. They can also inform structural changes to clinical practice that may increase the implementation of the best treatment strategies across settings to improve long-term outcomes for TRLLD.
KW - antidepressant
KW - older adults
KW - provider perspectives
KW - psychotherapy
KW - qualitative research
KW - treatment-resistant depression
UR - http://www.scopus.com/inward/record.url?scp=85120899196&partnerID=8YFLogxK
U2 - 10.1111/jgs.17592
DO - 10.1111/jgs.17592
M3 - Article
C2 - 34862593
AN - SCOPUS:85120899196
SN - 0002-8614
VL - 70
SP - 1190
EP - 1197
JO - Journal of the American Geriatrics Society
JF - Journal of the American Geriatrics Society
IS - 4
ER -